New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
16:13 EDTCPHDCepheid sees FY13 non-GAAP EPS 41c-46c, consensus 12c
Sees FY13 revenue $375M-$385M, consensus $396.52M. Sees FY13net income to range from a net loss of (5c)-1c. Expected non-GAAP net income excludes approximately $29M related to stock compensation expense and approximately $4M related to the amortization of acquired intangibles. The fully diluted share count for the year is expected to be approximately 72M, except in the event of a GAAP loss where the share count would be approximately 67M shares.
News For CPHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
16:09 EDTCPHDCepheid receives FDA emergency use authorization for Xpert Ebola diagnostic test
Cepheid announced it has received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert Systems. Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April. Cepheid's Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.
March 19, 2015
08:57 EDTCPHDCepheid has a conference call hosted by JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use